Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBNNASDAQ:DAWNNASDAQ:EOLSNASDAQ:IMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$8.82+2.8%$6.83$4.81▼$13.88$189.43M0.6262,275 shs482,953 shsDAWNDay One Biopharmaceuticals$6.95+0.3%$6.97$6.08▼$16.76$704.47M-1.31.12 million shs754,559 shsEOLSEvolus$9.74-0.6%$10.47$8.67▼$17.82$628.00M1.11721,078 shs592,334 shsIMTXImmatics$5.78+0.5%$4.62$3.30▼$13.77$702.56M0.83649,500 shs303,189 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin+3.13%+5.93%+32.00%+15.01%+2,225.20%DAWNDay One Biopharmaceuticals-0.72%+9.83%-7.35%-23.85%-45.73%EOLSEvolus-1.61%+5.38%-18.40%-27.41%-23.79%IMTXImmatics-2.21%+11.87%+12.75%+19.79%-53.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYBNCybin1.8759 of 5 stars3.60.00.00.00.60.81.3DAWNDay One Biopharmaceuticals1.9049 of 5 stars3.60.00.00.03.32.50.0EOLSEvolus3.5898 of 5 stars3.50.00.03.52.32.50.6IMTXImmatics2.0418 of 5 stars3.62.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$86.00875.06% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57339.88% UpsideEOLSEvolus 3.00Buy$23.75143.84% UpsideIMTXImmatics 3.20Buy$14.67153.75% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, EOLS, DAWN, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/ADAWNDay One Biopharmaceuticals$161.92M4.35N/AN/A$3.98 per share1.75EOLSEvolus$275.46M2.28N/AN/A($0.36) per share-27.06IMTXImmatics$144.15M4.87N/AN/A$2.88 per share2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/ADAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)EOLSEvolus-$61.69M-$0.89N/AN/AN/A-22.33%-847.60%-22.15%7/30/2025 (Estimated)IMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)Latest CYBN, EOLS, DAWN, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24DAWNDay One BiopharmaceuticalsN/A14.6214.55EOLSEvolus20.582.472.23IMTXImmaticsN/A3.983.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%DAWNDay One Biopharmaceuticals87.95%EOLSEvolus90.69%IMTXImmatics64.41%Insider OwnershipCompanyInsider OwnershipCYBNCybin15.00%DAWNDay One Biopharmaceuticals6.20%EOLSEvolus5.90%IMTXImmatics3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5021.48 million17.96 millionNot OptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableEOLSEvolus17064.48 million59.46 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableCYBN, EOLS, DAWN, and IMTX HeadlinesRecent News About These CompaniesMillennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX)June 5 at 3:23 AM | marketbeat.comImmatics: Taking Off On A PRAME RocketshipJune 4 at 10:05 AM | seekingalpha.comDoes Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?June 3 at 10:56 AM | zacks.comImmatics rises on data from early stage cell therapy trialJune 2 at 11:33 PM | msn.comImmatics Presents Promising IMA203 Data at ASCO 2025June 2 at 7:41 AM | tipranks.comImmatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock NewsJune 1, 2025 | gurufocus.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...May 31, 2025 | gurufocus.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...May 31, 2025 | gurufocus.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...May 31, 2025 | gurufocus.comImmatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic MelanomaMay 31, 2025 | quiverquant.comImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic MelanomaMay 31, 2025 | globenewswire.comImmatics (NASDAQ:IMTX) Receives $17.00 Consensus Target Price from AnalystsMay 31, 2025 | americanbankingnews.comWellington Management Group LLP Grows Position in Immatics (NASDAQ:IMTX)May 30, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Trading Up 4.1% - Time to Buy?May 29, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Given Average Recommendation of "Buy" by BrokeragesMay 29, 2025 | marketbeat.comDeutsche Bank Aktiengesellschaft Initiates Coverage on Immatics (NASDAQ:IMTX)May 29, 2025 | marketbeat.comDeutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy RecommendationMay 29, 2025 | msn.comDeutsche Bank Aktiengesellschaft Begins Coverage on Immatics (NASDAQ:IMTX)May 29, 2025 | americanbankingnews.comImmatics (NASDAQ:IMTX) Cut to Strong Sell at StockNews.comMay 24, 2025 | marketbeat.comWoodline Partners LP Cuts Stock Holdings in Immatics (NASDAQ:IMTX)May 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Buys 793,200 Shares of Immatics (NASDAQ:IMTX)May 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, EOLS, DAWN, and IMTX Company DescriptionsCybin NYSE:CYBN$8.82 +0.24 (+2.80%) Closing price 04:00 PM EasternExtended Trading$8.95 +0.13 (+1.47%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Day One Biopharmaceuticals NASDAQ:DAWN$6.95 +0.02 (+0.29%) Closing price 04:00 PM EasternExtended Trading$6.94 0.00 (-0.07%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Evolus NASDAQ:EOLS$9.74 -0.06 (-0.61%) Closing price 04:00 PM EasternExtended Trading$9.67 -0.07 (-0.72%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Immatics NASDAQ:IMTX$5.78 +0.03 (+0.52%) Closing price 04:00 PM EasternExtended Trading$5.79 +0.01 (+0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
